MUC-1/WT1 peptide-primed autologous dendritic cells

{
  "id": "MLC-T-ONC-015334",
  "term": "MUC-1/WT1 peptide-primed autologous dendritic cells",
  "field": "Oncology and biomedicine",
  "definition": "A cell-based cancer vaccine composed of autologous monocyte-derived dendritic cells (DCs) loaded with the human tumor-associated antigens (TAAs) mucin-1 (MUC1) and Wilms tumor protein 1 (WT1), with potential immunomodulating and antineoplastic activities. Upon vaccination, the MUC-1/WT1 peptide-primed autologous DCs expose the immune system to MUC1 and WT1 peptides and may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against MUC1 and WT1-expressing cancer cells, which could result in cancer cell lysis. MUC1 and WT1, are overexpressed in a variety of tumor types and play an important role in tumor cell proliferation.",
  "synonyms": [
    "MUC-1/WT1 peptide-primed autologous DCs",
    "MUC-1/WT1 peptide-loaded autologous dendritic cells"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/muc-1-wt1-peptide-primed-autologous-dendritic-cells/"
}